News
Sobi and Apellis Pharmaceuticals have reported new results from the open-label period of the randomised Phase III VALIANT ...
Otsuka Pharmaceutical has shared positive results from a late-stage study of its investigational monoclonal antibody ...
Sobi & Apellis’ Aspaveli/Empaveli demonstrates sustained one-year efficacy in phase 3 study for rare kidney diseases: Stockholm Monday, June 9, 2025, 10:00 Hrs [IST] Sobi, a glo ...
SHANGHAI, China I June 9, 2025 I Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback